Compare FSUN & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | VIR |
|---|---|---|
| Founded | 1892 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2017 | 2019 |
| Metric | FSUN | VIR |
|---|---|---|
| Price | $40.16 | $10.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $45.00 | $19.43 |
| AVG Volume (30 Days) | 238.1K | ★ 1.6M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.00 | 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $79.34 | $270.22 |
| Revenue Next Year | $14.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.95 | $4.75 |
| 52 Week High | $42.34 | $11.66 |
| Indicator | FSUN | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 59.30 | 74.11 |
| Support Level | $39.38 | $8.43 |
| Resistance Level | $40.35 | $11.66 |
| Average True Range (ATR) | 0.75 | 0.52 |
| MACD | -0.14 | 0.26 |
| Stochastic Oscillator | 48.59 | 94.79 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments; Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.